XML 65 R52.htm IDEA: XBRL DOCUMENT
v3.19.1

License agreements - Lilly (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended | 112 Months Ended
--- | --- | --- | --- | ---
Mar. 31, 2016 | Jul. 31, 2010 | Dec. 31, 2009 | Jun. 30, 2019 | Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2012 | Dec. 31, 2010 | Mar. 31, 2019
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Expense |  |  |  |  | $ 270,545 | $ 303,103 |  |  |  |  |  |
Revenues |  |  |  |  | 497,857 | 382,282 |  |  |  |  |  |
Product royalty revenues |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  | 61,608 | 47,716 |  |  |  |  |  |
Eli Lilly |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received under license agreement |  |  | $ 90,000 |  |  |  |  |  |  |  |  |
Product royalties in accounts receivable |  |  |  |  | $ 16,200 |  | $ 14,000 |  |  |  |  | $ 16,200
Eli Lilly | Maximum |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Associated future global development costs from the initiation of a Phase IIb trial, if elected to co-develop (as a percentage) | 20.00% |  |  |  |  |  |  |  |  |  |  |
Eli Lilly | Phase IIB |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Funding of future development costs (as a percent) |  | 30.00% |  | 30.00% | 30.00% |  |  |  |  |  |  |
Research and Development Expense |  |  |  |  | $ 0 | 12,500 |  |  |  |  |  |
Accrued and other liabilities |  |  |  |  | 0 |  | 23,100 |  |  |  |  | 0
Eli Lilly | Pre-specified Events | Maximum |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Upfront and immediate milestone payment to be received under license agreement |  |  | 665,000 |  |  |  |  |  |  |  |  |
Eli Lilly | Development Milestones |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  | 20,000 | $ 30,000 |  |  |  | 149,000
Eli Lilly | Development Milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Upfront and immediate milestone payment to be received under license agreement |  |  | 150,000 |  |  |  |  |  |  |  |  |
Eli Lilly | Development Milestones | Phase III |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  |  |  | $ 50,000 |  |
Eli Lilly | Development Milestones | Phase IIA |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  |  |  |  | $ 30,000 |
Eli Lilly | Development Milestones | Phase IIB |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  |  |  |  | $ 19,000 |
Eli Lilly | Regulatory Milestones |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  | $ 100,000 |  |  |  |  | $ 235,000
Eli Lilly | Regulatory Milestones | JAPAN |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  | 15,000 |  |  |  |
Eli Lilly | Regulatory Milestones | U.S. |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  |  | $ 35,000 |  |  |
Eli Lilly | Regulatory Milestones | Europe |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  | $ 65,000 | $ 20,000 |  |  |
Eli Lilly | Regulatory Milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Upfront and immediate milestone payment to be received under license agreement |  |  | 365,000 |  |  |  |  |  |  |  |  |
Eli Lilly | Commercialization Milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Upfront and immediate milestone payment to be received under license agreement |  |  | $ 150,000 |  |  |  |  |  |  |  |  |
Eli Lilly | Development and Commercialization Milestones |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  | 0 | 0 |  |  |  |  |  |
Eli Lilly | GVHD |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment under license agreement | $ 35,000 |  |  |  |  |  |  |  |  |  |  |
Additional milestone payments under the license agreement | $ 40,000 |  |  |  |  |  |  |  |  |  |  |
Eli Lilly | Product royalty revenues |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  | $ 16,000 | $ 6,400 |  |  |  |  |  |

X
- Definition Represents the additional milestone payments to be made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementAdditionalMilestonePayments
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of future global development costs funded under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded
Namespace Prefix: | incy_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of the upfront payment made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementUpfrontPaymentAmountPaid
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the upfront and immediate milestone payment received under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the upfront payment received under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementUpfrontPaymentReceived
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications. + References No definition available. + Details
Name: | incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds
Namespace Prefix: | incy_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty payment receivable under the license agreement. + References No definition available. + Details
Name: | incy_RoyaltyPaymentReceivable
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + References No definition available. + Details
Name: | us-gaap_AccruedLiabilitiesAndOtherLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=incy_EliLillyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_PhasesOfArrangementsAxis=incy_PhaseTwoBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_PreSpecifiedEventsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_PhasesOfArrangementsAxis=incy_PhaseThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_PhasesOfArrangementsAxis=incy_PhaseTwoAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_JP
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_DevelopmentAndCommercializationMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=incy_GvhdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |